
pmid: 28189178
Thrombotic thrombocytopenia purpura (TTP) and the hemolytic uremic syndrome (HUS) are rare thrombotic microangiopathies that can be rapidly fatal. Although the acquired versions of TTP and HUS are generally highest on this broad differential, multiple rarer entities can produce a clinical picture similar to TTP/HUS, including microangiopathic hemolysis, renal failure, and neurologic compromise. More recent analysis has discovered a host of genetic factors that can produce microangiopathic hemolytic syndromes. This article discusses the current understanding of thrombotic microangiopathy and outlines the pathophysiology and causative agents associated with each distinct syndrome as well as the most accepted treatments.
Adjuvants, Immunologic, Purpura, Thrombotic Thrombocytopenic, Thrombotic Microangiopathies, Hemolytic-Uremic Syndrome, ADAMTS13 Protein, Humans, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents
Adjuvants, Immunologic, Purpura, Thrombotic Thrombocytopenic, Thrombotic Microangiopathies, Hemolytic-Uremic Syndrome, ADAMTS13 Protein, Humans, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 73 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
